Zhitong Finance App News, Heyu-B (02256) announced that Shanghai Heyu Biomedical Technology Co., Ltd. (Fuyu Pharmaceutical), a subsidiary of the company, announced that the new drug clinical trial (IND) application for the oral, high-potency, and highly selective small molecule Pan-KRAS inhibitor ABSK211 being developed by the company to treat patients with advanced solid tumors with Kras gene changes has been approved by the US Food and Drug Administration (FDA). This is a voluntary announcement issued by the Company. The Group cannot guarantee that ABSK211 will eventually be successfully approved for listing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.